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Abstract
Background: Community Acquired Pneumonia (CAP) is a commonly encountered disease, one third of which is
Severe Community Acquired Pneumonia (SCAP) that can be potentially fatal. There is a paucity of data on etiology
and outcome of patients with SCAP in South Asian Population.
Methods: A retrospective cross-sectional study was conducted from March 2002 till December 2008 on patients of
16 years and above who were admitted with the diagnosis of SCAP in accordance to the criteria of American
Thoracic Society Guidelines (2001). The patients underwent clinical and diagnostic evaluations to detect the severity
of illness as well as the etiology and other risk factors influencing the eventual outcome of SCAP.
Results: A total of 189 patients were included in the study. The mean age was 60 ± 18.0 years and 110 (58%)
patients were males. The most common isolated pathogens were Staphylococcus aureus (15 patients), Streptococcus
pneumoniae (14 patients) and Pseudomonas aeruginosa (9 patients). The highest mortality was seen in patients with
Pseudomonas aeruginosa (89%) and Staphylococcus aureus (53%). Overall mortality rate was 51%. On univariate
analysis, septic shock (p <0.001), prior antibiotic use (p = 0.04), blood urea nitrogen > 30 mg/dl (p = 0.03), hematocrit
< 30% (p = 0.03) and Acute Physiology and Chronic Health Evaluation (APACHE) II score > 20 (p < 0.001) were
significantly different between the patients who survived as compared to those who did not. On multivariate
analysis, septic shock (p <0.001, OR: 4.70; 95% CI= 2.49-8.87) was found to be independently associated with
mortality.
Conclusion: The microbes causing SCAP in our study are different from the usual spectrum. Staphylococcus aureus
and Pseudomonas aeruginosa were the common causative pathogens and associated with high mortality. It is
important to establish clinical guidelines for managing SCAP according to the etiologic organisms in our setting.
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Background
Community Acquired Pneumonia (CAP) is a frequently
encountered lower respiratory tract parenchymal lung
infection which continues to be a major health problem
leading to significant morbidity and mortality worldwide
[1]. The annual incidence of CAP varies from 5–11 per
1,000 population with the rates being higher in the eld-
erly [1]. It presents a significant economic burden with
the yearly cost amounting to US$12 billion [2]. The wide
clinical spectrum of CAP varying from a mild self
limiting infection to widespread sepsis leading to organ
failure and death can be a daunting challenge for a phys-
ician to deal with.
Severe Community Acquired Pneumonia (SCAP) occurs
in approximately 18-36% [3] of all CAP. The mortality rate
for CAP is <5% for outpatient cases, it rises to 10% in admit-
ted ward patients and can exceed 30% in patients admitted
to intensive care unit (ICU) [4]. Tan et al. and Hirani et al.
reported a mortality rate of 67% and 58% in patients with
SCAP, respectively [3,5]. SCAP patients may require inten-
sive care monitoring, mechanical ventilation and prolonged
hospitalization, resulting in further economic burden espe-
cially in developing countries. Furthermore, despite the
advancements in diagnosing and managing CAP in the past
decades, the outcome remains unsatisfactory [5].* Correspondence: alianwar90@hotmail.com1Medical College, The Aga Khan University Hospital, PO Box # 3500, Stadium
Road, Karachi 74800, Pakistan
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Although guidelines exist for the initial empirical treat-
ment of SCAP [6,7], the emergence and spread of
drug-resistant pathogens (including Penicillin-resistant
Streptococcus pneumoniae), variations in the etiological
agents, prevalence of atypical pathogens in different
geographical locations and the seriousness of illness
which demands initiation of treatment prior to reaching
an etiologic diagnosis have led to ambiguities. It is hence
imperative that these recommendations should be based
on the epidemiological data obtained from a particular
geographic location. There is paucity of data on SCAP in
South Asia and the physicians tend to follow the
American and British guidelines for managing this dis-
ease. Our study aimed to identify the etiological agents
responsible for SCAP cases in a tertiary care hospital
setting in Pakistan. We also assessed the factors influ-
encing mortality and the actual outcome of patients
with SCAP admitted in this setting.
Methods
A retrospective cross-sectional study was conducted by
the Section of Pulmonary and Critical Care Medicine at
the Aga Khan University Hospital (AKUH), Karachi,
from March 2002 till December 2008. AKUH is a major
tertiary care hospital serving more than 10 million
people of Karachi and the surrounding region. With an
operational strength of 650 beds, the facility serves over
42,000 inpatients and over 500,000 outpatients annually.
Established since 1985, it is one of the few teaching
hospitals in South Asia accredited by the Joint Commis-
sion for International Accreditation [8].
All patients of age 16 years and above who were ad-
mitted with the diagnosis of SCAP in accordance to the
criteria by American Thoracic Society guidelines (2001)
were included in the study [6]. Patients who were trans-
ferred from another hospital and those who developed
pneumonia after 48 hours of hospitalization or endo-
tracheal intubation were excluded from the study to rule
out hospital-acquired pneumonia. Patients less than 16 -
years of age and those who were immunocompromised
(having underlying malignancy, undergoing chemotherapy
or radiation, using high dose systemic corticosteroids and
known HIV positive status) were also excluded from the
study.
CAP was diagnosed on the basis of patient’s symptoms
suggestive of pulmonary infection (fever, cough, sputum
production, abnormal leukocyte count, pleuritic chest
pain, signs of consolidation on examination) and chest x-
ray finding of lung infiltrate. SCAP was defined as CAP
associated with the presence of one major or two or
more minor criteria. The major criteria included a need
for mechanical ventilation and septic shock. The minor
criteria included systolic BP ≤ 90 mmHg, bilateral pneu-
monia or multilobar pneumonia and PaO2/FIO2 ≤ 250.
The medical record numbers of patients are saved and
coded according to the diagnoses at our institution. File
records with primary diagnosis of pneumonia were
extracted using the medical record numbers and re-
viewed. Imaging and laboratory software was used to re-
view the radiology and laboratory and microbiological
data. The recorded data included demographics of the
patients including age, gender, comorbids, laboratory
investigations including leukocyte count, platelet count,
blood urea nitrogen and creatinine and arterial blood
gases done on admission. Chest radiographs and cultures
obtained within 48 hours of admission and outcome of
the patients were evaluated. Chest radiographs were read
by two experts separately and the mutual conclusions on
the findings were obtained. The microbiological data
comprised cultures of the respiratory tract (sputum,
tracheal or endobronchial aspirate or bronchoalveolar lav-
age), acid fast bacilli smear and mycobacterial sputum
cultures (in selected cases) and blood cultures. Serological
testing for atypical bacteria and viruses was not performed
due to non-availability of tests. The severity of illness was
determined at the time of admission or transfer to the
ICU within 48 hours of hospitalization. Mortality was
defined as death of a patient during his or her hospital
stay.
Data analysis
The statistical analysis was conducted by using the Statis-
tical package for social science SPSS (Release 16.0 standard
version, copyright © SPSS). A descriptive analysis was
performed for demographic and clinical characteristics
and results are presented as mean ± standard deviation for
quantitative variables and numbers (percentages) for quali-
tative variables. In univariate analysis, association between
outcomes of SCAP and its risk factors was assessed by
using the Chi-square test or Fisher exact test where appro-
priate. For contrasts of continuous variables, independent
sample t-test was used to assess the difference of means.
Univariable analyses were performed to examine the effect
of each variable on the poor outcome. A forward stepwise
selection method was used and variables significantly
associated with the outcome of P < 0.05 were retained in
the final model. To assess multivariate associations be-
tween the outcomes and potential covariates, odds ratios
(ORs) and their 95% confidence intervals (CIs) were
computed by logistic regression analysis.
Ethical approval
Due to the retrospective nature of the study, a written
informed consent could not be obtained from the
participants. However, the study was done in compliance
to International Helsinki Declaration and formal ap-
proval was taken from the Ethical Review Committee
(ERC) of the Aga Khan University Hospital prior to
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commencement of the study. Identification of study
participants was kept strictly confidential throughout the
duration of the study.
Results
General characteristics of patients
A total of 832 files were reviewed out of which 189
patients met the inclusion criteria. The mean age was
60 ± 18.0 years and 110 (58%) patients were males.
Twenty-nine (11%) patients had no co-morbid illnesses
on presentation while the rest had at least one under-
lying disease which included cardiovascular disease
(59%), pulmonary disease (42%) and diabetes mellitus
(35%) (Table 1).
Microbial etiology of patients
Blood cultures were performed in all the patients while
respiratory (sputum, tracheal aspirate, BAL) and pleural
fluid cultures were available for 164 and 20 patients,
respectively. Of 189 patients, 47 (25%) had an identifi-
able microbial etiology (Table 2). The most common
isolated pathogens were Staphylococcus aureus (15
patients), Streptococcus pneumoniae (14 patients) and
Pseudomonas aeruginosa (9 patients). Mycobacterium
tuberculosis was diagnosed in 2 patients. Nocardia
asteroides and Streptococcus milleri were found in one
patient each; both organisms were isolated from pleural
fluid culture. Besides the 100% mortality observed in
three patients with Moraxella catarrhalis, Burkholderia
pseudomallei and Nocardia asteroids respectively, the
highest mortality was seen in patients with Pseudomonas
aeruginosa (89%) and Staphylococcus aureus (53%).
Risk factors for mortality in patients
Chest radiography revealed bilateral lung involvement in
89 (47%), isolated right lung involvement in 64 (34%),
isolated left lung involvement in 35 (19%) and medias-
tinal involvement in one patient. The most common
finding was consolidation; 119 (63%) followed by pleural
Table 1 Demographic, clinical, laboratory and
radiographic characteristics of patients diagnosed with
severe community acquired pneumonia (n = 189)
Characteristics Number of patients
(percentage)
Age in years (Mean ± S.D.) 60 ± 18.0
Gender
Male 110 (58%)
Female 79 (42%)
Underlying comorbids
Cardiovascular diseases 111 (59%)
Hypertension 92 (49%)
Ischemic heart disease 52 (28%)
Congestive heart failure 12 (06%)
Pulmonary diseases 79 (42%)
COPD 34 (18%)
Asthma 21 (11%)
Bronchiectasis 11 (06%)
History of Tuberculosis 10 (05%)
Pulmonary fibrosis 07 (04%)
Diabetes mellitus 66 (35%)
Others 52 (28%)
Chronic renal failure 41 (22%)
Chronic liver disease 11 (06%)
Laboratory data
Hemoglobin (g/dL) 11.4 ± 2.7
Hematocrit (%) 34.2 ± 8.2
Total Leukocyte count (x 109/L) 18.3 ± 13.5
Neutrophils (%) 82.0 ± 18.5
Lymphocytes (%) 11.4 ± 14.9
Plateletes (x 109/L) 243 ± 138.5
Serum BUN (mg/dL) 41.0 ± 25.5
Serum Creatinine (mg/dL) 2.4 ± 2.2
Serum Sodium (mmol/L) 135.0 ± 7.4
Serum Potassium (mmol/L) 4.2 ± 0.9
Serum Bicarbonate (mmol/L) 20.0 ± 6.7
Serum Chloride (mmol/L) 102.0 ± 10.0
Arterial Blood Gases
pH 7.36 ± 0.12
PaCO2 (mmHg) 38.0 ± 18.0
PaO2 (mmHg) 79.0 ± 26.0
Chest radiography
Bilateral involvement 89 (47%)
Unilateral involvement (Right) 64 (34%)
Unilateral involvement (Left) 35 (19%)
Mediastinal involvement 01 (0.5%)
Consolidation 119 (63%)
Table 1 Demographic, clinical, laboratory and
radiographic characteristics of patients diagnosed with
severe community acquired pneumonia (n = 189)
(Continued)
Pleural effusion 70 (37%)
Interstitial infiltrates 53 (28%)
Atelectasis 30 (16%)
Cavitation 06 (03%)
Nodules 05 (03%)
Single lobe 123 (65%)
Multilobar 66 (35%)
Khawaja et al. BMC Infectious Diseases 2013, 13:94 Page 3 of 6
http://www.biomedcentral.com/1471-2334/13/94
effusion in 70 (37%) and interstitial infiltrates in 53
(28%) patients (Table 1).
Out of 189 patients, 179 were admitted in ICU while 10
patients were managed in the wards. The average length
of hospital stay was 10.2 ± 10.7 days with an average ICU
and ward stay of 7 and 3 days, respectively. Eighty-four
(44.4%) patients improved and were discharged home, 9
(4.7%) patients either left against medical advice or were
shifted to another hospital due to non availability of venti-
lator machine and 96 (51%) patients died. Amongst all
deaths, 59 (61%) occurred due to shock, 18 (19%) due to
cardiac arrythmias, 17 (18%) due to respiratory failure and
2 (2%) were caused by multiorgan failure.
On univariate analysis, septic shock (p <0.001), prior
antibiotic use in past 2 weeks (p = 0.04), blood urea ni-
trogen > 30 mg/dl (p = 0.03), hematocrit < 30% (p = 0.03)
and Acute Physiology and Chronic Health Evaluation
(APACHE) II score > 20 (p < 0.001) were statistically dif-
ferent between survivors and non-survivors (Table 3).
After adjusting for significant variables in the univariate
analysis, multivariate analysis revealed septic shock
(p <0.001, OR: 4.70; 95% CI = 2.49-8.87) to be inde-
pendently associated with mortality.
Discussion
Several studies have published clinical and epidemiological
data on CAP, but very few have reported the data on SCAP,
particularly in South Asian population. In this study, a spe-
cial emphasis was given to identify the common etiological
agents and outcomes associated with SCAP.
The diagnostic yield of 25% in this study was low in
comparison to other studies of SCAP [9-12]. The most
plausible explanations for the low yield is the non-
availability and high cost of serological tests essential for
the identification of atypical organisms like Mycoplasma
pneumoniae, Legionella pneumophila and Chlamydia
pneumoniae and frequent use of antibiotic in the com-
munity. Atypical pathogens have been the major cause
of CAP in some studies from the west with Legionella
pneumophila type 1 causing 1-30% [5,13,14] of adult
cases and Mycoplasma pneumoniae being implicated in
20-30% [15,16] as an etiological agent.
Streptococcus pneumoniae was found to be the second
most common pathogen accounting for pneumonia in
around 7% of the patients. This percentage is lower
when compared to the western countries where Strepto-
coccus pneumoniae is reported in 24-45% of the patients
with CAP and SCAP [5,9-14]. The most crucial aspect
of our study was a high proportion of Staphylococcus
aureus and Pseudomonas aeruginosa as the causative
agents. Generally, these organisms are more associated
with hospital acquired infection and less commonly
reported for community acquired pneumonia [11,17].
However, amongst studies from the west, Pachon et al.
reported gram negative bacilli in 25% of patients
diagnosed with SCAP [13]. Ruiz et al. reported 4 out of
47 patients with known etiology to be infected with
Pseudomonas aeruginosa in Spain [14] while a more re-
cent study in the same region found 8 out of 39 patients
to have Pseudomonas aeruginosa pneumonia in ICU
patients [18]. Another study in Russia found Staphylo-
coccal aureus and Pseudomonas aeruginosa to be im-
portant etiological agents in SCAP [19]. On the contrary
in the Asian continent, the most common organisms
isolated in patients from India were Pseudomonas
aeruginosa (35%) and Staphylococcus aureus (24%) [20].
A relatively higher prevalence of Pseudomonas aeruginosa
and Staphylococcus aureus has also been reported in Japan
Table 2 Isolation of bacteria from patients admitted with severe community acquired pneumonia (n = 189)
Etiological agent No. of patients
with positive cultures
No. of patients
who died
Staphylococcus aureus (7 from blood culture, 5 from tracheal aspirate, 1 from BAL, 2 from sputum) 15 8 (53)
Streptococcus pneumonia (11 from blood culture, 1 from tracheal aspirate, 2 from sputum) 14 4 (29)
Pseudomonas aeruginosa (3 from blood culture, 3 from tracheal aspirate, 2 from BAL, 1 from sputum) 9 8 (89)
Klebsiella pneumonia (5 from tracheal aspirate, 1 from BAL) 6 3 (50)
Mycobacterium tuberculosis (2 from BAL) 2 1 (50)
Moraxella catarrhalis (Tracheal aspirate) 1 1 (100)
Burkholderia pseudomallei (Tracheal aspirate) 1 1 (100)
Nocardia asteroids (Pleural fluid) 1 1 (100)
Streptococcus milleri (Pleural fluid) 1 0
Number of pathogens isolated 50 27 (54)
Number of patients with known etiology* 47 25 (53)
Number of patients with unknown etiology 142 71 (50)
The values in the brackets are the percentages of patients who died with positive cultures.
*Three patients had dual etiologies: Staphylococcus aureus and Pseudomonas aeruginosa in two and Pseudomonas aeruginosa and Nocardia asteroides in one
patient.
Khawaja et al. BMC Infectious Diseases 2013, 13:94 Page 4 of 6
http://www.biomedcentral.com/1471-2334/13/94
and China [21-24] indicating microbiological spectrum
specific to certain epidemiological areas. Wu et al.
reported around 23% of the patients to have Pseudomonas
aeruginosa while another study in Japan reported 17% and
11% of the patients to have Staphylococcal aureus and
Pseudomonas aeruginosa associated SCAP, respectively
[23,24]. We found only two cases of pulmonary tubercu-
losis leading to SCAP in contrast to a study from
Singapore in which 16% of the patients were diagnosed to
have pulmonary tuberculosis [3]. Other studies in Asia
particularly Singapore and Thailand have highlighted the
presence of Burkholderia pseudomallei (3, 9) which is not
prevalent in our setting. Hemophilus influenzae and
Moraxella catarrhalis were also not isolated, possibly due
to their inability to cause severe disease.
The physical examination and chest radiography fin-
dings did not vary significantly between the patients who
survived and those who did not. Although higher num-
ber of deaths was observed in patients who required
mechanical ventilation and those with bilateral involve-
ment of lungs, these were not statistically significant.
APACHE II score was significantly increased in non-
survivors on univariate analysis. History of prior antibiotic
use in last 2 weeks, BUN ≥ 30 mg/dl and hematocrit < 30%
were significantly associated with high mortality on
univariate analysis. Prior antibiotic use particularly in last
3 months is a well identified risk factor for colonization
and infection associated with multi-drug resistant (MDR)
pathogens [25,26]. However, on multivariate analysis, sep-
tic shock was the only variable independently associated
with mortality in our study.
The overall mortality of patients in our study was lower
than those reported by other Asian studies (3, 22), compar-
able to a recent Japanese study (21) and higher than western
studies (10–14). However, low mortality was also seen in a
study from Thailand [9] while a high mortality was observed
in United Kingdom [5]. This reflects the wide variability that
exists between SCAP outcomes in different settings and
geographical regions. In our study, infection with Pseudo-
monas aeruginosa was associated with worst outcome as 8
out of 9 patients infected with this pathogen died. Staphylo-
coccus aureus was also associated with a high mortality rate
of 53%. In contrast to a study by Moine et al. in France
where Streptococcus pneumoniae was significantly associated
with mortality (35% patients) [12], it was relatively less fatal
in our study. Klebsiella pneumoniae pneumonia which is
common in European countries and highly associated with
alcoholism and mortality [11] was also less common in our
setting, possibly due to limited use of alcohol. The mortality
in patients with identified etiology was almost the same as
in patients in which no organism was isolated. The overall
higher mortality could also be attributed to other factors like
lack of national health care services, poverty, decreased level
of awareness and health related myths and practices in gen-
eral population.
The major limitation of our study was the lack of
availability of serological tests for the diagnosis of viral
and atypical pathogens. Furthermore, no set protocol
was followed for the identification of microbial etiology.
Investigations were done mainly on the discretion of the
primary physician. Due to low percentage of patients with
etiological identification, risk factors of patients with
Staphylococcus aureus and Pseudomonas aeruginosa infec-
tion could not be ascertained. Risk stratification scores
such as Pneumonia Severity Index (PSI) could not be
calculated due to retrospective collection of data. Pro-
spective trials would be required to further assess the
Table 3 Differences in clinical characteristics between
survivors and non survivors (Univariate analysis)
Clinical features Survivors
(n = 93)
Non
survivors
(n = 96)
p value
Demographic factors
Mean age 59.3 ± 18.6 61.0 ±17.4 0.52
≥ 65 years age 48 (52%) 52 (54%) 0.73
Gender male/female 55/38 55/41 0.79
ATS major criteria
Use of mechanical
ventilation
18 (19%) 29 (30%) 0.08
Septic shock 23 (25%) 59 (61%) < 0.001
History
Prior antibiotic use 14 (15%) 26 (27%) 0.04
Comorbids 76 (82%) 84 (88%) 0.27
Physical examination
findings
Blood pressure≤
90/60 mmHg
25 (27%) 30 (31%) 0.51
Pulse≥ 120/min 32 (34%) 37 (39%) 0.55
Respiratory Rate
30/min
56 (60%) 57 (59%) 0.95
Laboratory findings
Blood urea nitrogen≥
30 mg/dl
44 (47%) 59 (61%) 0.03
Creatinine > 1.5 mg/dL 48 (52%) 53 (55%) 0.25
Hematocrit <30% 22 (24%) 37 (39%) 0.03
Na <130 mmol/L 22 (24%) 28 (29%) 0.39
Arterial pH <7.35 28 (30%) 32 (33%) 0.63
Radiographic findings
Pleural effusion 32 (34%) 38 (40%) 0.46
Bilateral involvement 36 (39%) 53 (55%) 0.07
Multilobar
involvement
28 (30%) 38 (40%) 0.22
Mean APACHE II score 19.1 ±6.0 28.2 ±7.0 <0.001
APACHE II score ≥ 20 38 (41%) 80 (83.0%) <0.001
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indicators of severity and management of disease includ-
ing time to admission to ICU, time to antimicrobial
treatment, diagnosis of bacteremia and whether initial
antimicrobial treatment was appropriate. Lastly, this was a
single center study and hence, cannot be generalized to
the whole population.
Conclusion
In conclusion, the microbial spectrum causing SCAP
found in this study varies considerably from the west.
Staphylococcus aureus and Pseudomonas aeruginosa
were amongst the most common causative pathogens and
highly associated with mortality. This highlights the im-
portance of a development of local pneumonia guidelines
focusing on its etiology and management.
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